Back to results
US 9,068,000 B2Granted
Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
AssigneeThe University of North Carolina at Chapel Hill
InventorsDavid R. Clemmons, Laura A. Maile
Life of this patent
Estimating the term…
Abstract
The present invention provides αVβ3 integrin cysteine loop domain agonists and antagonists (including peptide agonists and antagonists and analogs thereof), along with methods of using the same.
Claims7
A method of inhibiting IGF-1 actions in a subject in need of treatment for retinopathy, comprising administering to the subject an effective amount of an antibody that:
- (a) specifically binds to the cysteine loop domain at amino acids 177 to 184 of a human β3 integrin, wherein said amino acids consist of SEQ ID NO:82;
- (b) does not specifically bind to the RGD binding site of a human β3 integrin or utilize the RGD binding site of human β3 integrin;
- and (c) specifically binds to the cysteine loop domain at amino acids 177 to 184 of a pig β3 integrin, wherein said amino acids consist of SEQ ID NO:82, thereby inhibiting IGF-1 actions in the subject and treating the retinopathy in the subject.
Dependencies are inferred from the claim text.